Literature DB >> 2995303

Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits.

J R Perfect, D T Durack.   

Abstract

We studied the penetration of two imidazoles (ketoconazole and vibunazole) and two triazoles (itraconazole and UK-49,858) into cerebrospinal fluid (CSF) of rabbits with and without meningitis. There were wide differences in degree of penetration of these drugs into CSF, from less than 3% to 66% of simultaneous serum concentrations. UK-49,858, which has little protein-binding, penetrated freely while itraconazole, which is highly protein-bound, could not be detected in CSF. Intermediate concentrations of vibunazole and ketoconazole were found in CSF. Presence of meningeal inflammation modestly increased CSF concentrations of ketoconazole but had no significant effect on penetration of the other three drugs. The excellent penetration of UK-49,858 indicates that it has promise for treatment of CNS fungal infections.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995303     DOI: 10.1093/jac/16.1.81

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  34 in total

1.  Systemic antifungal agents.

Authors:  L O Gentry
Journal:  Tex Heart Inst J       Date:  1990

2.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

3.  High-dose itraconazole in the treatment of severe mycoses.

Authors:  P K Sharkey; M G Rinaldi; J F Dunn; T C Hardin; R J Fetchick; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

4.  Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates.

Authors:  T J Walsh; C Lester-McCully; M G Rinaldi; J E Wallace; F M Balis; J W Lee; P A Pizzo; D G Poplack
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Authors:  G S Kobayashi; S J Travis; M G Rinaldi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

6.  Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.

Authors:  J R Perfect; K A Wright; M M Hobbs; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

7.  Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  D Debruyne; J P Ryckelynck; M Moulin; B Hurault de Ligny; B Levaltier; M C Bigot
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

8.  Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis.

Authors:  Perparim Kamberi; Raymond A Sobel; Karl V Clemons; Andreas Waldvogel; Joan M Striebel; Paul L Williams; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

9.  Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome.

Authors:  J de Gans; J K Eeftinck Schattenkerk; R J van Ketel
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-30

Review 10.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.